Financial Performance - Total profit decreased by 78.46% to ¥181,174,862.02 compared to ¥841,095,361.37 in the previous year[6] - Net profit fell by 78.17% to ¥141,885,482.96 from ¥650,063,599.37 year-on-year[6] - Operating profit declined by 78.76% to ¥178,819,355.74, primarily due to reduced gross profit and increased investment losses[3] - Total operating revenue for the period was CNY 4,063,233,063.48, a decrease of 24.69% compared to the same period last year[25] - Net profit attributable to shareholders of the listed company was CNY 143,170,121.26, down 78.05% year-on-year[25] - Basic earnings per share decreased by 85.97% to CNY 0.0135[25] - The company reported a net profit of CNY 141,885,482.96 for the period, a decrease of 78.05% compared to the previous year[21] Cash Flow - Cash flow from operating activities improved by 67.47%, reaching -¥233,988,970.92, compared to -¥719,281,089.84 in the previous year[7] - The company's cash flow from operating activities showed a net outflow of CNY 233,988,970.92, an increase of 67.47% compared to the same period last year[25] - The net cash flow from operating activities for the current period was -233,988,970.92 CNY, compared to -719,281,089.84 CNY in the previous period[30] - The cash inflow from other operating activities was 47,790,265.82 CNY, down from 72,009,536.97 CNY in the previous period[30] - The company reported a decrease in cash outflow for purchasing goods and services, which was 3,633,091,884.41 CNY compared to 5,322,980,702.09 CNY in the previous period[32] Assets and Liabilities - The company’s total assets decreased by 63.85% in trading financial assets, dropping to ¥474,182,329.41 from ¥1,311,642,406.30[2] - As of September 30, 2023, the company's total assets amounted to approximately CNY 20.12 billion, a decrease from CNY 20.84 billion at the beginning of the year, reflecting a decline of about 3.47%[12] - The company's current assets totaled CNY 11.86 billion, down from CNY 12.39 billion, indicating a decrease of approximately 4.29%[15] - Total liabilities amounted to CNY 7,621,518,381.46, down from CNY 8,435,034,680.42[25] - Current liabilities totaled CNY 4,997,191,595.42, down from CNY 5,575,796,301.03 at the beginning of 2023, reflecting a reduction of approximately 10.4%[39] - The total liabilities decreased to CNY 7,621,518,381.46 from CNY 8,435,034,680.42, a reduction of approximately 9.6%[39] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 27,307[8] - The largest shareholder, Shenzhen Lerun Technology Co., Ltd., holds 32.31% of the shares, totaling 474,029,899 shares[8] - The company has a total of 10 major shareholders, with Shenzhen Lerun Technology Co., Ltd. holding 474,029,899 shares, representing approximately 4.09% of the total share capital[11] Investment and Development - The company reported a significant increase in long-term equity investments, which rose to CNY 666.69 million from CNY 989.39 million, indicating a decrease of about 32.61%[15] - The company is exploring new strategies for market expansion and product development, although specific details were not disclosed in the report[14] - The company is focusing on expanding its market presence and enhancing product development capabilities to drive future growth[41] Financial Accuracy and Reporting - The report for the third quarter has not been audited[43] - The board of directors guarantees the accuracy and completeness of the financial information disclosed in the quarterly report[46] - The company has confirmed that there are no false records or misleading statements in the quarterly report[47] - The financial information in the quarterly report is stated to be true, accurate, and complete by the responsible personnel[47]

Financial Performance - Total revenue for Q3 2023 was RMB 1,350,333,671.41, a decrease of 17.49% compared to the same period last year[3] - Net profit attributable to shareholders for Q3 2023 was RMB 19,820,280.08, down 85.95% year-on-year[3] - Net profit excluding non-recurring items for Q3 2023 was RMB 5,738,544.66, a decline of 95.33% compared to the previous year[3] - Basic earnings per share for Q3 2023 was RMB 0.0135, down 85.97% year-on-year[3] - The company reported a total revenue of RMB 4,063.2 million for the reporting period, a decrease of 24.6% compared to RMB 5,395.2 million in the same period last year[10] - Gross profit for the reporting period was RMB 1,342.6 million, down from RMB 1,740.6 million year-on-year, with a gross margin of 33.0%, slightly up from 32.3%[10] - Net profit attributable to shareholders was RMB 143.2 million, a significant decline of 78.1% from RMB 652.3 million in the previous year[10] - Operating profit decreased by 78.76% to RMB 178.8 million, primarily due to reduced gross profit and increased investment losses[8] - The total profit for the current period is 181,174,862.02, a significant decrease of 78.5% compared to 841,095,361.37 in the previous period[23] - Net profit attributable to shareholders of the parent company is 143,170,121.26, down 78.1% from 652,257,852.66 in the previous period[23] - The total comprehensive income for the current period is 242,978,158.09, a decrease of 76.3% compared to 1,027,254,477.99 in the previous period[24] Cash Flow and Assets - Cash flow from operating activities for the year-to-date period was RMB -233,988,970.92, an increase of 67.47% compared to the same period last year[3] - The company experienced a 67.47% improvement in net cash flow from operating activities, amounting to RMB -233.99 million, compared to RMB -719.28 million in the previous year[9] - Cash inflow from operating activities is 4,858,315,550.55, down 20.1% from 6,083,780,203.37 in the previous period[26] - Cash outflow from operating activities totals 5,092,304,521.47, a decrease of 25.1% compared to 6,803,061,293.21 in the previous period[26] - Cash and cash equivalents decreased to RMB 1,791,292,771.63 from RMB 2,138,779,146.48, reflecting a decline of 16.2%[18] - Total assets at the end of the reporting period were RMB 20,120,561,011.47, a decrease of 3.33% from the previous year[3] - Total assets decreased to RMB 20,120,561,011.47 from RMB 20,844,503,816.18, a decline of 3.5%[21] - Current assets decreased to RMB 11,859,083,872.73 from RMB 12,389,647,370.74, reflecting a decline in liquidity[31] - Inventory increased to RMB 7,805,326,066.17, up 14.0% from RMB 6,843,906,474.31[19] - Accounts receivable decreased to RMB 1,241,350,011.62 from RMB 1,598,311,315.68, a reduction of 22.4%[18] Liabilities and Equity - Total liabilities decreased to RMB 7,621,518,381.46 from RMB 8,435,034,680.42, a reduction of 9.6%[21] - Current liabilities totaled RMB 4.99 billion, down from RMB 5.58 billion at the start of 2023, indicating a decrease of about 10.4%[33] - Long-term borrowings increased to RMB 2.12 billion from RMB 1.80 billion, reflecting a rise of approximately 17.6%[33] - Total equity attributable to shareholders rose to RMB 12.41 billion, up from RMB 12.31 billion at the beginning of the year, marking an increase of about 0.9%[34] - The company reported a decrease in accounts payable from RMB 427.43 million to RMB 213.34 million, a reduction of approximately 50%[32] Business Strategy and Market Position - The company faced challenges in the heparin raw material business, with demand and industry shipment volumes remaining weak, significantly impacting performance[11] - The company aims to strengthen its market position in the heparin sodium preparation sector and expand its market coverage in both domestic and international markets[11] - The company plans to enhance its marketing efforts for API and CDMO services to attract new customers and ensure high-quality business development[10] - The company is actively seeking collaboration opportunities with third parties to navigate the current macroeconomic challenges and industry pressures[10] - The CDMO business continues to be driven by Cytovance Biologics, Inc. and SPL Acquisition Corp., focusing on enhancing existing customer collaborations and exploring service extensions[12] - The company aims to expand its customer base and diversify order structures by actively developing small and medium-sized clients[12] - The company is integrating R&D resources and production capacity to improve clinical trial quality and efficiency, supporting future business growth[12] - The company is adjusting its business strategy based on different development potentials and market conditions, aiming to enhance competitive strength and market share[13] - The company is closely monitoring regional market demands and adjusting operational investments to strengthen its market position in Europe and the US[13] - The company is committed to maintaining a product platform and supply chain that exceeds industry benchmarks, focusing on enhancing organizational capabilities across the entire value chain[13] - The company is actively developing the number of clients and projects in the CDMO sector, aiming to accelerate the release of business value[13] - The company is exploring new opportunities to build differentiated competitive advantages and achieve stable high-quality development[13] Shareholder Information - The top ten shareholders hold significant stakes, with Shenzhen Lerun Technology Co., Ltd. owning 32.31% and Xiamen Jintian Investment Partnership holding 27.81%[14] - The company has a total of 27,307 common shareholders, indicating a broad base of ownership[14] Other Financial Metrics - The company reported a net investment loss of RMB -274,834,971.73, compared to a loss of RMB -81,921,282.69 in the previous period[22] - Research and development expenses were RMB 152,223,825.20, a decrease from RMB 166,593,528.66 in the previous period[22] - The company reported a decrease in other comprehensive income after tax to RMB 101,092,675.13 from 377,190,878.62 in the previous period[23] - Basic and diluted earnings per share are both 0.0976, down from 0.4445 in the previous period[24] - The fair value change income is 37,143,775.77, a recovery from a loss of -14,746,578.38 in the previous period[23] - The third quarter report was not audited, indicating that the figures are preliminary and subject to change[35]

Financial Performance - The company reported a significant increase in revenue, achieving a total of CNY 1.5 billion in the first half of 2023, representing a year-on-year growth of 25%[2]. - For the six months ended June 30, 2023, revenue was RMB 3,756,335, a significant increase compared to RMB 1,218,477 for the same period in 2022[12]. - Total revenue for the six months ended June 30, 2023, was RMB 2,706,246, a decrease of 28.0% compared to RMB 3,756,335 in 2022[49]. - Profit for the period decreased to RMB 122,366 from RMB 510,404 in the previous year, indicating a decline in profitability[12]. - The profit attributable to equity holders decreased by 75.9% to RMB 123.3 million, while adjusted profit excluding investment losses increased to RMB 340.3 million[18]. - The total comprehensive income for the period was RMB 230,198,000, a decline of 67% compared to RMB 701,063,000 in the previous year[119]. - Profit before tax decreased to RMB 167.7 million, compared to RMB 629.0 million in the prior year, representing a decline of approximately 73.3%[117]. User Growth and Market Expansion - User data showed a 30% increase in active users, reaching 2 million by the end of June 2023[2]. - Market expansion plans include entering two new international markets by Q4 2023, targeting an additional CNY 500 million in revenue[2]. - The company provided a positive outlook for the second half of 2023, projecting a revenue growth of 20% to 25%[2]. Product Development and R&D - The company is investing CNY 200 million in R&D for new technologies aimed at enhancing product efficacy[2]. - New product launches are expected to contribute an additional CNY 300 million in revenue by the end of 2023[2]. - The Group has obtained exclusive development and commercial rights in China for certain clinical stage innovative drug candidates targeting immune system-related diseases[14]. Cost Management and Profitability - The gross margin improved to 55%, up from 50% in the previous year, due to cost optimization strategies[2]. - The company aims to reduce operational costs by 10% through efficiency improvements in the supply chain[2]. - The gross profit for the same period was RMB 2,706,246, resulting in a gross profit margin of 35.4%, up from 32.4% in 2022[12]. - The Group's heparin industrial chain business achieved sales revenue of RMB 2,289.5 million, down from RMB 3,268.9 million in the same period last year[21]. Strategic Initiatives - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of CNY 1 billion allocated for potential deals[2]. - A new strategic partnership was announced, expected to enhance distribution channels and increase market penetration[2]. - The Group's subsidiary Techdow USA Inc. entered into a distribution agreement with Chia Tai Tianqing Pharmaceutical Group, aligning with the Group's internationalization strategy[19]. Financial Position and Assets - Total assets as of June 30, 2023, were RMB 20,787,431, slightly down from RMB 20,814,204 at the end of 2022[12]. - The equity attributable to owners of the parent increased to RMB 12,397,624 from RMB 12,310,915, reflecting a positive trend in shareholder equity[12]. - The asset-liability ratio improved to 39.9% from 40.4%, indicating a stronger financial position[12]. Market Conditions and Economic Outlook - The global economic growth forecast for 2023 was lowered to 3.0%, with developed economies expected to grow only 1.5%[15]. - China's GDP growth for the first and second quarters of 2023 was reported at 4.5% and 6.3% year-on-year, showing significant recovery[15]. Shareholder Information and Corporate Governance - The Board consists of six Directors, including three executive Directors and three independent non-executive Directors[80]. - The company has complied with all applicable provisions of the Corporate Governance Code during the reporting period[109]. - The company declared dividends to shareholders, reflecting ongoing shareholder returns[128]. Financial Instruments and Risks - The Group reported a tax-adjusted unrealized foreign exchange gain of RMB 79.1 million during the reporting period[68]. - The Group plans to utilize financial market tools to mitigate foreign exchange loss risks and will actively promote internal loan conversion approval processes[68]. - The company reported foreign exchange losses of RMB 126,847, compared to losses of RMB 102,886 in the same period of 2022, indicating an increase of 23.3%[196].

Financial Performance - The company reported a significant increase in revenue, achieving a total of 70 million in the first half of 2023, reflecting a growth of 12% compared to the same period last year[2]. - The company reported a revenue of RMB 1.5 billion for the first half of 2023, representing a year-on-year increase of 15%[64]. - The net profit attributable to shareholders for the same period was RMB 300 million, up 20% compared to the previous year[64]. - The company's operating revenue for the reporting period was ¥2,712,899,392.07, a decrease of 27.82% compared to the same period last year[83]. - Net profit attributable to shareholders was ¥123,349,841.18, down 75.87% year-on-year[83]. - The net cash flow from operating activities was -¥542,751,701.14, representing a decline of 125.45% compared to the previous year[83]. - The company's heparin API business revenue was approximately RMB 698 million, a year-on-year decline of 56.63%[151]. - The company reported a total of CNY 357.09 million in new purchases of financial assets during the period[139]. - The company reported a net investment loss of ¥226,299,845.92, which accounted for -134.92% of total profit[162]. Strategic Focus and Growth - The company is focusing on expanding its global supply chain for raw materials to mitigate risks associated with price fluctuations and supply shortages, particularly for heparin raw materials[17]. - The company has established a pipeline of innovative drug candidates, with several in clinical stages, aiming for commercialization in the near future[19]. - The company is actively enhancing its CDMO services, benefiting from the growing demand in the biopharmaceutical market, which has seen an increase in client R&D budgets[18]. - The company is prioritizing the development of new technologies and products to strengthen its market position and drive future growth[19]. - The company plans to launch three new products in the next quarter, focusing on innovative drug formulations[64]. - The company is expanding its market presence in Southeast Asia, targeting a 30% market share by the end of 2024[64]. - A strategic acquisition of a local biotech firm is expected to enhance the company's R&D capabilities and product pipeline[64]. - The company is focusing on deepening partnerships with strategic allies to secure high-quality orders and enhance project reserves[18]. Risk Management - The company is implementing strategies to manage foreign exchange risks, as a significant portion of its revenue is derived from overseas markets, primarily in euros and US dollars[20]. - The company faces potential risks from changes in international laws, political environments, and trade sanctions affecting overseas operations[26]. - The company is enhancing quality control measures to mitigate product quality risks associated with complex production processes[31]. - The company is facing risks related to raw material supply constraints and the inability to timely pass on costs[36]. - The company has established a risk control mechanism for foreign exchange derivative trading to mitigate exchange rate fluctuations[39]. Investment and Financial Assets - The company has made strategic investments in several innovative drug development firms, which may impact its financial performance due to fluctuations in fair value[21]. - The company has not engaged in speculative derivative investments during the reporting period[41]. - The company’s financial derivative trading is based on self-owned funds and adheres to legal and prudent principles[39]. - The company reported a loss of 0.89 million CNY from the fair value change of RVX warrants during the reporting period[39]. - The company incurred a loss of 210.51 million CNY from foreign exchange derivative trading during the reporting period[39]. - The total financial assets at the end of the period amounted to approximately CNY 1.79 billion, reflecting a significant increase from the beginning of the period[139]. Market Position and Competition - The heparin raw material drug industry is highly competitive, with the company rapidly increasing market share in Europe through its proprietary enoxaparin sodium formulation[32]. - The company relies heavily on two main products: enoxaparin sodium formulation and heparin sodium raw materials, which poses a concentration risk[33]. - The company successfully won the first position in the eighth batch of national drug centralized procurement for its enoxaparin sodium formulation, which is expected to be a new growth point[101]. - The company is focusing on expanding its market share in China through active participation in drug procurement and leveraging its high-ranking bid advantages[101]. - The company is enhancing its sales network in the U.S. and establishing partnerships with various medical systems and distributors to drive business growth[151]. Research and Development - The company is engaged in both independent and collaborative R&D efforts to accelerate the launch of new drug varieties, including projects like H1710 and RVX-208[95]. - The company has developed approximately 200 different molecular structures in its CDMO business, supporting over 300 clinical trials[112]. - The company is currently developing a candidate drug in the oncology field that is in the preclinical stage, with 5 indications in global Phase III clinical trials[113]. - The company has established a long-term stable partnership with several well-known multinational pharmaceutical companies for heparin raw materials[111]. - The company has over 20 first-in-class drug candidates covering more than 30 indications through industrial and equity investments[113]. Corporate Governance - The company has undergone a board restructuring with several directors being elected or leaving due to term completion[24]. - The annual shareholders' meeting had an investor participation rate of 68.34%[29]. - The board has decided not to distribute cash dividends for this fiscal year, focusing on reinvestment for growth[64].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. （深圳市海普瑞藥業集團股份有限公司） （於中華人民共和國註冊成立的股份有限公司） （股份代號：9989） 截至二零二三年六月三十日止六個月之中期業績公告 深圳市海普瑞藥業集團股份有限公司（「本公司」、「公司」或「海普瑞」）董事會（「董 事會」）欣然宣佈本公司及其子公司（「本集團」或「我們」）截至二零二三年六月三十 日止六個月（「報告期」）之未經審核綜合中期業績，連同二零二二年同期的比較數字。 | --- | --- | --- | --- | --- | |-------------------------------------------------------------------------------------------|-------|--------------------------- ...

深圳市海普瑞药业集团股份有限公司 2023 年第一季度报告 深圳市海普瑞药业集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 3.第一季度报告是否经审计 1 （一）主要会计数据和财务指标 | --- | --- | --- | --- | |-----------------------------------------------------|-------------------|-------------------|----------------------------------| | | 本报告期 | 上年同期 | 本报告期比上年同期 | | | | | 增减（ % ） | | 营业收入（元） | 1,301,021,684.04 | 1,910,323,745.74 | -31.90% | | 归属于上市公司股东的净利润（元） | 66,540,023.25 | 234,943,371 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥1,301,021,684.04, a decrease of 31.90% compared to ¥1,910,323,745.74 in the same period last year[3]. - Net profit attributable to shareholders was ¥66,540,023.25, down 71.68% from ¥234,943,371.65 year-on-year[3]. - The net cash flow from operating activities was negative at ¥213,979,198.80, a significant decline of 15,418.93% compared to the previous year[3]. - Basic and diluted earnings per share were both ¥0.0453, reflecting a decrease of 71.71% from ¥0.1601 in the same period last year[3]. - Gross profit for the current period was RMB 454.0 million, down from RMB 579.2 million year-on-year, with a gross margin of 34.9%, up from 30.3%[12]. - Operating profit decreased by 74.02% to RMB 73.6 million, primarily due to a reduction in gross profit[9]. - The total comprehensive income for the current period is CNY 61,856,551.06, a decrease from CNY 230,706,330.71 in the previous period[32]. Assets and Liabilities - Total assets at the end of the reporting period were ¥20,623,022,731.91, a decrease of 0.92% from ¥20,814,206,782.52 at the end of the previous year[3]. - Total liabilities increased from CNY 8,406,564,448.47 to CNY 8,435,034,680.42, with an adjustment of CNY 28,470,231.95[24]. - Total assets amount to RMB 20,623,022,731.91, down from RMB 20,814,206,782.52, indicating a decrease of 0.9%[29]. - Total liabilities decreased to RMB 8,151,172,088.52 from RMB 8,406,564,448.47, reflecting a reduction of 3.0%[29]. - Non-current liabilities increased to RMB 3,016,772,193.42 from RMB 2,830,768,147.44, representing a growth of 6.6%[29]. Cash Flow - The company experienced a significant increase in cash flow from investment activities, reporting a net cash inflow of RMB 795.7 million, compared to a net outflow of RMB 88.0 million in the same period last year, representing a 1,003.94% increase[10]. - Cash inflow from operating activities is CNY 1,936,382,607.31, a slight decrease from CNY 1,964,042,020.61 in the previous period[34]. - Cash outflow from operating activities totals CNY 2,150,361,806.11, compared to CNY 1,965,420,847.89 in the previous period[35]. - Net cash flow from investment activities is CNY 795,650,734.04, a significant improvement from CNY -88,020,516.24 in the previous period[36]. - Net cash flow from operating activities is negative at CNY -213,979,198.80, compared to CNY -1,378,827.28 in the previous period[35]. Market and Sales Strategy - The company’s heparin sodium product sales volume and market share have rapidly increased over the past five years, becoming a key revenue growth driver[11]. - The company plans to strengthen its sales layout in Europe, where it holds a top two market share position, and will continue to expand its presence in untapped markets[13]. - The company is actively pursuing diversified marketing strategies and expanding sales territories to overcome current challenges[14]. - The company aims to optimize its supply chain management and resource distribution to support the expansion of its main business[11]. - The company received FDA approval for its heparin sodium injection, allowing for self-marketing in the U.S. market, marking a significant breakthrough[12]. Shareholder Information - The top ten shareholders hold significant stakes, with Shenzhen Lerun Technology Co., Ltd. owning 32.31% and Urumqi Jintian Investment Partnership holding 27.81%[18]. - The top ten shareholders include Shenzhen Le Ren Technology Co., holding 474,029,899 shares, and Urumqi Jintian Equity Investment Partnership, holding 408,041,280 shares, indicating strong institutional support[19]. Research and Development - Research and development expenses for the current period are RMB 26,514,765.57, an increase of 27.1% compared to RMB 20,883,937.48 in the previous period[30]. - The CDMO business is driven by Cytovance Biologics, Inc. and SPL Acquisition Corp., focusing on integrating R&D resources and enhancing customer collaboration[15]. Strategic Collaborations - The company entered a licensing agreement with Youhua Biotech for the commercialization of Oregovomab in Taiwan, enhancing its strategic partnerships in the Greater China region[20]. - The company’s subsidiary Tian Dao America signed a distribution agreement with Zhengda Tianqing for the commercialization of Fosaprepitant in the US, marking a significant step in its overseas marketing efforts[20].

Financial Performance - Revenue for 2022 reached RMB 7,151,039, an increase of 12.4% compared to RMB 6,359,786 in 2021[6] - Profit before tax for 2022 was RMB 829,851, representing a 273.5% increase from RMB 222,264 in 2021[6] - Profit attributable to owners of the Company for the year was RMB 727,077, up from RMB 240,788 in 2021, marking a significant increase of 202.5%[6] - For the year ended December 31, 2022, the Group achieved operating revenue of RMB 7,151 million, representing an increase of 12.4% compared to the previous year[11] - The gross profit margin for the year was 32.0%, an increase of 0.7 percentage points from the previous year[11] - Profit attributable to owners of the Company amounted to RMB 727.1 million, reflecting a year-on-year growth of 202.0%[12] - The sales of finished dose pharmaceutical products increased by 21.7% to RMB 3,210.5 million, while API sales decreased by 1.8% to RMB 2,673.8 million[27] - The CDMO service segment saw a significant growth of 33.3%, with operating income reaching RMB 1,084.1 million[27] - The Group's gross profit margin improved compared to the previous year, indicating better cost control and operational efficiency[24] - The Group's financial summary for the last five financial years is available on page 5 of the annual report[84] Assets and Liabilities - Total assets as of 2022 amounted to RMB 20,814,204, an increase from RMB 19,108,177 in 2021[7] - Total liabilities increased to RMB 8,406,565 in 2022, compared to RMB 7,584,862 in 2021[7] - Equity attributable to shareholders of the Company was RMB 12,310,915 in 2022, up from RMB 11,411,354 in 2021[7] - The asset-liability ratio was approximately 40.4% as of December 31, 2022, compared to approximately 39.7% as of December 31, 2021[55] - The Group's interest-bearing borrowings amounted to approximately RMB 6,317.5 million as of December 31, 2022, up from approximately RMB 5,518.4 million as of December 31, 2021[62] Market Expansion and Strategy - The Company plans to expand its market presence and invest in new product development in the upcoming year[6] - The management highlighted ongoing research and development efforts aimed at enhancing product offerings and technological advancements[6] - The Company is exploring potential mergers and acquisitions to strengthen its market position and drive growth[6] - Hepalink aims to enhance its digitalization capabilities and build an integrated production and sales model to improve operational efficiency and reduce costs[15] - The Group plans to strengthen its supply chain management to effectively control procurement costs and improve profit margins[15] - The Company is committed to becoming a leading innovative multinational pharmaceutical company globally by strengthening its core competencies[15] Sales and Distribution - Global sales volume in 2022 exceeded 227 million units, up 22.3% year-on-year, while sales revenue increased by 12.4% compared to the same period last year[12] - The Company achieved sales expansion in over 30 provinces and cities in China and entered into drug procurement catalogs of various regions[12] - Sales in the U.S. market maintained steady growth, with the Group's enoxaparin sodium finished doses becoming a market leader, supported by contracts with the three largest distributors and major Group Purchasing Organizations[30] - Sales in the China market exceeded 13 million units, representing an increase of more than 50%, with successful expansion into over 30 provinces and cities nationwide[30] - The Group's enoxaparin sodium injection brand, Prolongin, became the first to achieve online sales cooperation with multiple internet platforms in China[30] Research and Development - Hepalink has obtained exclusive development and commercial interest in Greater China for certain clinical stage innovative drug candidates targeting immune system diseases[17] - The global Phase III study of AR-301 enrolled 174 subjects, with 120 cases in the modified intention to treat (mITT) analysis, showing benefits for patients over 65 years old[37] - Oregovomab demonstrated a median progression-free survival (PFS) of 41.8 months in combination with chemotherapy, compared to 12.2 months for chemotherapy-only, with a hazard ratio (HR) of 0.46[37] - The critical technology R&D project for H1710 has been approved by the Science, Technology and Innovation Commission of Shenzhen[38] - The company is focused on innovative drug R&D, ensuring effective allocation and management of resources for clinical development[44] Corporate Governance - The Company aims to achieve good corporate governance standards to safeguard shareholder interests and enhance corporate value[149] - The Board comprises 6 Directors, including 3 executive Directors and 3 independent non-executive Directors[150] - The roles of Chairman and Chief Executive Officer are held by different individuals, ensuring compliance with governance standards[152] - The Company has received written annual confirmations of independence from all independent non-executive Directors, affirming their independence[152] - The Company has established a code of conduct for securities trading by its directors and senior management, ensuring compliance with required standards[149] Shareholder Engagement - The Company has established a shareholders' communication policy to ensure effective engagement with shareholders and regular reviews of its effectiveness[186] - The Board considers the implementation and effectiveness of the shareholders' communication policy to be sufficient and adequate during the reporting period[187] - The Company aims to maintain ongoing dialogue with shareholders through annual general meetings and other meetings[186] - The Group's largest customer accounted for 10.3% of total revenue, while the five largest customers contributed 31.7% of total revenue during the reporting period[140] Risk Management - The Company has established a robust internal control system to manage various potential risks related to its strategic plan, research and development, and other operational aspects[176] - The Board has reviewed the risk management and internal control systems and deemed them effective and adequate for the Reporting Period[177] - The Company has implemented measures to manage potential conflicts of interest between the Group and its Controlling Shareholders[176] - The Company faces risks related to market acceptance, pricing controls, and reimbursement policies that could adversely affect operations and profitability[146] Future Outlook - The global macroeconomic environment in 2023 is expected to be challenging, with China's economic rebound contrasting with recession risks in Europe and the U.S.[39] - The Company is optimistic about future prospects and will continue to implement its existing strategy while exploring new opportunities for business breakthroughs[45] - The management has set a revenue target of $500 million for the upcoming fiscal year, representing a 10% increase from the current year[64]

Dividend Distribution - The company plans to distribute a cash dividend of 1.00 yuan per 10 shares to all shareholders, based on a total of 1,467,296,204 shares[4]. - The company distributed a cash dividend of 0.35 yuan per 10 shares based on a total share capital of 1,467,296,204 shares, approved at the 2021 annual general meeting[92]. - The cash dividend policy complies with the company's articles of association and has been transparently executed[93]. Financial Performance - The company reported a revenue of RMB 1.5 billion for the fiscal year 2022, representing a year-over-year growth of 15%[39]. - The company's total revenue for 2022 was RMB 7,159,410,684.41, primarily from the production and sales of heparin raw materials and formulations, as well as contract development and manufacturing organization (CDMO) services[113]. - The net profit for the year reached CNY 714,687,211.31, a significant increase compared to CNY 233,383,425.18 from the previous year, representing a growth of about 206.5%[191]. - The company's operating profit improved to CNY 828,623,184.85, up from CNY 227,474,697.78, marking an increase of around 264.5%[191]. - The company reported a decrease in accounts payable from CNY 171,477,883.69 to CNY 99,991,386.43, a reduction of about 41.7%[187]. - The total liabilities reached CNY 8,406.56 million, compared to CNY 7,584.86 million in the previous period, marking an increase of approximately 10.8%[183]. Future Guidance and Growth - The company has set a revenue guidance for 2023 at RMB 1.8 billion, indicating a projected growth of 20%[39]. - User data showed an increase in active users by 20% to 2 million in the same period[39]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[46]. - New product development includes a breakthrough in monoclonal antibody technology, expected to launch in Q3 2023[46]. Compliance and Governance - The company has maintained its commitment to transparency, with all financial reports signed and stamped by responsible parties[24]. - The company retained Ernst & Young Hua Ming as the domestic auditor for the 2022 financial report, with total audit fees amounting to RMB 5.58 million and internal control audit fees of RMB 0.43 million[54]. - The audit committee reviewed and agreed on the annual financial reports and internal control evaluations for 2021[153]. - The company has established a series of plans to ensure timely and full repayment of its bonds, including dedicated departments and personnel, and strict execution of financial management plans[88]. Employee and Management Information - The total number of employees at the end of the reporting period was 2,366, with 936 in the parent company and 1,430 in major subsidiaries[158]. - The company has established a competitive salary system based on performance and capability, ensuring fair compensation across different positions[158]. - Total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 1,396.48 million[176]. Risk Management - The company has detailed its future risks and countermeasures in the annual report, highlighting the importance of investor awareness regarding investment risks[19]. - The company has not reported any changes in its main business operations since its listing[32]. - The company has not reported any major matters that require explanation during the reporting period[65]. Financial Health Indicators - The company's EBITDA to total debt ratio improved to 21.40%, an increase of 8.47% compared to the previous year[106]. - The current ratio decreased by 1.14% to 2.222, while the quick ratio dropped by 21.39% to 0.9946[106]. - The debt-to-asset ratio increased to 40.39%, up by 0.70% from the previous year[106]. - Interest coverage ratio improved significantly to 4.53, a 115.71% increase from 2.10 in the previous year[130]. Asset and Liability Management - The total assets increased to CNY 14,483,308,913.97 from CNY 14,324,415,709.31, reflecting a growth of approximately 1.11%[187]. - Non-current liabilities totaled CNY 2,830.77 million, slightly up from CNY 2,793.39 million, indicating a growth of about 1.3%[183]. - The company's capital reserve decreased to CNY 5,858.62 million from CNY 5,943.65 million, a decline of about 1.4%[183]. Strategic Investments - The company has invested RMB 200 million in sustainable practices, aiming for a 30% reduction in waste emissions by 2025[46]. - The company has established partnerships with leading technology firms to enhance its production processes and product offerings[46]. - The company has made strategic investments in new product development and technology, although specific figures are not provided in the content[194].

Revenue and Profitability - Revenue increased by 12.4% to RMB 7,151.0 million (2021: RMB 6,359.8 million) [2] - Profit attributable to equity holders of the parent increased by RMB 486.3 million or 202.0% to RMB 727.1 million [2] - Net profit attributable to equity holders increased by 202.0% to RMB 727.1 million, with basic earnings per share rising to RMB 0.50 from RMB 0.16 in 2021 [11] - Gross profit was RMB 2,290.2 million (2021: RMB 1,993.6 million), with a gross margin of 32.0%, up 0.7 percentage points [2] - Gross profit increased by RMB 296.6 million to RMB 2,290.2 million, compared to RMB 1,993.6 million in the same period last year, with a gross margin rise from 31.3% to 32.0% [38] Business Segments Performance - Formulation business sales revenue grew by 21.7% to RMB 3,210.5 million (2021: RMB 2,638.2 million) [2] - CDMO business sales revenue increased by 33.3% to RMB 1,084.1 million (2021: RMB 813.1 million) [2] - The pharmaceutical formulation segment achieved a revenue growth of 21.7%, totaling approximately RMB 3,210.5 million, accounting for 44.9% of total revenue [15] - CDMO services revenue grew by 33.3% to RMB 1,084.1 million, indicating strong demand in this segment [13] - The API business generated approximately RMB 2,673.8 million in sales revenue, accounting for 37.4% of total revenue, with a gross margin improvement to 27.7% [19] Market Expansion and Strategy - The company has established exclusive development and commercialization rights for several innovative drug candidates in Greater China, focusing on immune-related diseases [10] - The supply chain strategy has been enhanced to ensure material supply and operational efficiency amid global economic challenges [10] - The company is actively developing proprietary drug candidates currently in the preclinical stage [10] - The company actively expanded its market presence in France and Switzerland, further solidifying its position in Europe [16] - The company achieved significant sales growth in emerging markets such as Malaysia, Brazil, and Saudi Arabia, while also advancing international drug registration efforts [17] Financial Position and Assets - Total assets less current liabilities amounted to RMB 15,238.4 million (2021: RMB 14,316.7 million) [7] - Net assets attributable to equity holders of the parent increased to RMB 12,310.9 million (2021: RMB 11,411.4 million) [7] - Total assets as of December 31, 2022, were approximately RMB 20,814.2 million, compared to RMB 19,108.2 million as of December 31, 2021 [46] - Total liabilities as of December 31, 2022, were approximately RMB 8,406.6 million, compared to RMB 7,584.9 million as of December 31, 2021, resulting in a debt-to-asset ratio of approximately 40.4% [46] Dividends and Shareholder Returns - The board declared a final cash dividend of RMB 1.0 per ordinary share (tax included) for the year [2] - The proposed final dividend per ordinary share for 2022 is RMB 0.10, compared to RMB 0.035 in 2021, representing an increase of 185.7% [77] - The final dividend will be distributed to H shareholders no later than August 15, 2023, if approved [87] - The annual general meeting is scheduled for May 22, 2023, where the dividend proposal will be discussed [88] Research and Development - The AR-301 monoclonal antibody is currently in global Phase III clinical trials, with 174 subjects enrolled, showing promising results in reducing mechanical ventilation time for patients with ventilator-associated pneumonia [24] - Oregovomab's Phase II clinical trial demonstrated a median progression-free survival (PFS) of 41.8 months compared to 12.2 months for the control group, with a hazard ratio (HR) of 0.46 [25] - RVX-208 has completed Phase III trials and received FDA breakthrough therapy designation, aiming to reduce major adverse cardiovascular events in high-risk patients [27] - H1710, an acetyl heparinase inhibitor, has completed active pharmaceutical ingredient production and is preparing for IND application in both China and the US [28] Operational Efficiency and Cost Management - The sales cost increased by RMB 494.7 million to RMB 4,860.9 million, primarily due to rising costs in pharmaceutical formulations and CDMO services [35] - Financing costs rose by RMB 35.5 million to RMB 245.6 million, an increase of 16.9% compared to RMB 210.1 million in the same period last year [39] - The company aims to enhance global supply chain management and digital integration to improve operational efficiency and resilience [29] Compliance and Governance - The audit committee reviewed the consolidated annual performance for the year ended December 31, 2022, and confirmed compliance with relevant accounting standards [92] - The company's auditor confirmed that the financial figures in the performance announcement are consistent with the consolidated financial statements [93] - There are no post-reporting period matters requiring shareholder attention [94]